Почетна › Трипл негативен рак на дојка › Џорџија
Клинички испитувања за Трипл негативен рак на дојка во Џорџија
26 студии за Трипл негативен рак на дојка бараат учесници на локации во Џорџија.
Градови во Џорџија
Официјален текст на студијата (англиски)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Winship Cancer Institute of Emory University, Atlanta
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06270706A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Emory University, Atlanta
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06465069A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Emory Winship Cancer Institute, Atlanta
- Augusta University, Augusta
Се регрутираФаза 1
Возраст 19 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06586957A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- University Cancer & Blood Center, LLC ( Site 0023), Athens
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06966700A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT05570253Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University Cancer & Blood Center, LLC., Athens
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
- и уште 3
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06400472Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT05846789ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 31.8.2026 · NCT06460298A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 10.8.2026 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT05579366A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- University Cancer & Blood Center, Athens
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.7.2026 · NCT06150664A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 29.6.2026 · NCT05377996Study of XB010 in Subjects With Solid Tumors
- Winship Cancer Institute, Atlanta
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.6.2026 · NCT06545331BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Winship Cancer Institute / Emory University, Atlanta
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 15.6.2026 · NCT05768932A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Georgia Cancer Center, Augusta
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.6.2026 · NCT04300556Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
- Emory University Hospital, Atlanta
Се регрутираФаза 2
Возраст 18 и постари · Жени · Ажурирано 4.6.2026 · NCT05741164Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
- Emory University/Winship Cancer Institute, Atlanta
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст 18 и постари · Жени · Ажурирано 7.5.2026 · NCT05877859I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 6.5.2026 · NCT01042379High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
- Emory University Hospital/Winship Cancer Institute, Atlanta
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 17.4.2026 · NCT06492759Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
- Emory University, Winship Cancer Institute, Atlanta
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 25.2.2026 · NCT02926690A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Winship Cancer Institute - Emory University, Atlanta
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.1.2026 · NCT06926920Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- и уште 1
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 26.1.2026 · NCT06324240A Beta-only IL-2 ImmunoTherapY Study
- Emory - Winship Cancer Institute, Atlanta
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 9.7.2025 · NCT05086692A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Columbus Regional Research Institute, LLC, Columbus
Се регрутираФаза 3
Возраст од 18 до 65 · Жени · Ажурирано 21.3.2025 · NCT03671044Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.